Healthcare Professional Resources

Acertis is dedicated to supporting healthcare professionals in their mission to care for patients. That’s why we’ve put together a range of materials to help support clinicians.

What Makes Licart Different?

Licart® (diclofenac epolamine) topical system 1.3% is the only once-a-day topical nonsteroidal anti-inflammatory drug (NSAID) available for acute pain due to minor strains, sprains, and contusions. Its patented next-generation patch technology goes to work fast, for powerful pain relief that starts within 1-3 hours of first application and is applied once a day.1

Licart delivers medicine directly to where it hurts and has a low incidence of adverse events.3
With low systemic exposure, it may be appropriate for a wide variety of patients for a wide variety of pain sites. It is appropriate as either monotherapy or in combination with other pharmacologic or nonpharmacologic pain therapies.

Licart Next-Generation Patch Technology

Licart’s patented next-generation patch technology is clinically proven to reduce pain within 1-3 hours after first application and to continue to reduce pain when applied daily for 7 days.1

Licart also offers several other benefits over similar therapies, including:

  • Once-a-day dosing: Other topical NSAID analgesics may require multiple daily doses.
  • Fast onset: Many therapies require several hours or days to reach their full effect. Licart offers significant pain relief within 1-3 hours after first application.1
  • Low systemic exposure: Unlike oral therapies, Licart delivers powerful and targeted NSAID therapy with low systemic exposure (<1%).3
  • Easy application: Unlike diclofenac gel and liquid formulations that require measuring devices for precise dosing, Licart ensures a proper dose in one easy-to-apply patch. Patients just peel Licart from its package and stick it where it hurts.
  • No mess or odor: Topical NSAID gels and liquids may have an unpleasant odor and stick to or stain clothing. Licart is mess-free, has no unpleasant odor, and won’t stick to clothes.
  • Adherence: Licart’s hydrophilic gel adheres to skin so that patients don’t need to reapply.2

Product Samples

To order samples of Licart, fill out the Sample Request Form found at the link below. Please note that each Sample Request Form must be signed by a healthcare professional who is licensed to prescribe medication in the United States. In most cases, samples will be shipped within 3 business days after receipt of a fully completed request form. There is a limit of 1 shipment per month per licensed prescriber.

REQUEST SAMPLE

ICD-10 Codes

To see the full list of ICD-10 codes, click the button below.

ICD-10 CODES

Patient Savings Options

Acertis offers patients several ways to save on their Licart prescription. Click below to learn more about the Licart Copay Savings Card or the Licart Direct program. To learn which option may be better for your various patients, go to our Ways to Save page.

Licart Copay Savings Card
Licart Direct Program

Want to Connect With an Acertis Sales Representative?

To get in touch with a representative who can provide more information or answer your questions about Licart, email us at info@acertisrx.com.

Medical Information

For medical information, call 1-888-848-3593 or email virtus@medinfodept.com.

Report an Adverse Event

To report an Adverse Event or product quality complaint, call 1-888-848-3593 or email virtus@medinfodept.com, or call 1-800-FDA-1088 or visit fda.gov/medwatch. 

Downloadable Licart Prescription Pad

LICART PRESCRIPTION PAD

Read More ↗

INDICATIONS AND USAGE

LICART contains diclofenac epolamine, which is a nonsteroidal anti-inflammatory drug (NSAID), and is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS

Cardiovascular Thrombotic Events

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use.
  • LICART is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal Bleeding, Ulceration, and Perforation

  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

CONTRAINDICATIONS

LICART is contraindicated in the following patients:

  • Known hypersensitivity to diclofenac or any components of the drug product.
  • History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
  • In the setting of CABG surgery.
  • For use on non-intact or damaged skin.

WARNINGS AND PRECAUTIONS

  • Hepatotoxicity: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop.
  • Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. Monitor blood pressure.
  • Heart Failure and Edema: Avoid use of LICART in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure.
  • Renal Toxicity: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia. Avoid use of LICART in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function.
  • Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs.
  • Exacerbation of Asthma Related to Aspirin Sensitivity: LICART is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity).
  • Serious Skin Reactions: Discontinue LICART at first appearance of skin rash or other signs of hypersensitivity.
  • Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Discontinue and evaluate clinically.
  • Fetal Toxicity: Limit use of NSAIDs, including LICART, between about 20 to 30 weeks in pregnancy due to the risk of oligohydramnios/fetal renal dysfunction. Avoid use of NSAIDs in women at about 30 weeks' gestation and later in pregnancy due to the risks of oligohydramnios/fetal renal dysfunction and premature closure of the fetal ductus arteriosus.
  • Hematologic Toxicity: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia.

ADVERSE REACTIONS

Most common adverse reactions for LICART are application site pruritus and other application site reactions.
To report SUSPECTED ADVERSE REACTIONS, contact IBSA Pharma Inc. at: 1-800-587-3513 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.
For Full Prescribing Information, visit licart.com/wp-content/uploads/2023/10/Licart-Full-Prescribing-Information_2024.pdf.

Scroll to Top